Clinical Trial Update: UK Ibrance Patient Program (IPP) Study

View source ↗

Summary

Clinical trial update for the UK Ibrance Patient Program (IPP) study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Pfizer | Conditions: HR+/HER2- Locally Advanced, Metastatic Breast Cancer | Status: COMPLETED | Results posted: 2023-03-17